UPDATE: Barclays Downgrades Ariad Pharmaceuticals Following News of Iclusig Clinical Hold
October 10, 2013 at 11:35 AM EDT
In a report published Thursday, Barclays analyst Ying Huang downgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA ) from Overweight to Underweight, and lowered the price target from $25.00 to $4.00. In the report, Barclays noted, “We are downgrading ARIA to UW from OW and reducing our price target to
